TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Avecho Biotechnology Limited ( (AU:AVE) ) has provided an update.
Avecho Biotechnology Limited has received patent allowances in the US and Europe for its proprietary CBD soft-gel capsule formulation, which is in Phase III clinical trials for insomnia. These patents, expected to be granted by the end of FY26, will protect the formulation until at least 2040, enhancing Avecho’s intellectual property in major markets. This development strengthens Avecho’s position in cannabinoid formulation technology and supports future regulatory and commercial efforts. The ongoing clinical trial, the largest of its kind, aims to support the registration of the CBD TPM soft-gel capsule for insomnia treatment, potentially allowing Avecho to capitalize on a significant market opportunity in Australia.
More about Avecho Biotechnology Limited
Avecho Biotechnology Limited is a company that develops and commercializes innovative health products for humans and animals using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM). TPM, derived from Vitamin E, enhances the solubility and absorption of drugs and nutrients. Avecho’s lead product is a CBD TPM soft-gel capsule, currently in Phase III clinical development for treating insomnia.
Current Market Cap: A$33.06M
See more data about AVE stock on TipRanks’ Stock Analysis page.